Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Cardiomyocyte microRNA-150 confers cardiac protection and directly represses proapoptotic small proline–rich protein 1A
Tatsuya Aonuma, Bruno Moukette, Satoshi Kawaguchi, Nipuni P. Barupala, Marisa N. Sepúlveda, Christopher Corr, Yaoliang Tang, Suthat Liangpunsakul, R. Mark Payne, Monte S. Willis, Il-man Kim
Tatsuya Aonuma, Bruno Moukette, Satoshi Kawaguchi, Nipuni P. Barupala, Marisa N. Sepúlveda, Christopher Corr, Yaoliang Tang, Suthat Liangpunsakul, R. Mark Payne, Monte S. Willis, Il-man Kim
View: Text | PDF
Research Article Cardiology Cell biology

Cardiomyocyte microRNA-150 confers cardiac protection and directly represses proapoptotic small proline–rich protein 1A

  • Text
  • PDF
Abstract

MicroRNA-150 (miR-150) is downregulated in patients with multiple cardiovascular diseases and in diverse mouse models of heart failure (HF). miR-150 is significantly associated with HF severity and outcome in humans. We previously reported that miR-150 is activated by β-blocker carvedilol (Carv) and plays a protective role in the heart using a systemic miR-150 KO mouse model. However, mechanisms that regulate cell-specific miR-150 expression and function in HF are unknown. Here, we demonstrate that potentially novel conditional cardiomyocyte–specific (CM-specific) miR-150 KO (miR-150 cKO) in mice worsens maladaptive cardiac remodeling after myocardial infarction (MI). Genome-wide transcriptomic analysis in miR-150 cKO mouse hearts identifies small proline–rich protein 1a (Sprr1a) as a potentially novel target of miR-150. Our studies further reveal that Sprr1a expression is upregulated in CMs isolated from ischemic myocardium and subjected to simulated ischemia/reperfusion, while its expression is downregulated in hearts and CMs by Carv. We also show that left ventricular SPRR1A is upregulated in patients with HF and that Sprr1a knockdown in mice prevents maladaptive post-MI remodeling. Lastly, protective roles of CM miR-150 are, in part, attributed to the direct and functional repression of proapoptotic Sprr1a. Our findings suggest a crucial role for the miR-150/SPRR1A axis in regulating CM function post-MI.

Authors

Tatsuya Aonuma, Bruno Moukette, Satoshi Kawaguchi, Nipuni P. Barupala, Marisa N. Sepúlveda, Christopher Corr, Yaoliang Tang, Suthat Liangpunsakul, R. Mark Payne, Monte S. Willis, Il-man Kim

×

Figure 5

SPRR1A is a direct target of miR-150 and is upregulated in patients with heart failure.

Options: View larger image (or click on image) Download as PowerPoint

SPRR1A is a direct target of miR-150 and is upregulated in patients wit...
(A) Human SPRR1A has a miR-150 binding site. miR-150 seed pairing in the target region is presented as vertical lines. (B) The ability of miR-150 to directly inhibit the activity of luciferase (LUC) reporter constructs that contain either WT or mutated (MUT) binding site for SPRR1A. Transfection with or without miR-150 mimic in H9c2 cells is shown. Firefly LUC activity was normalized to Renilla LUC activity and compared with empty vector measurements. Results are representative of 6 independent experiments with different biological samples. Unpaired 2-tailed t test. *P < 0.05 versus miR mimic control. (C) qPCR expression analysis of SPRR1A in heart tissues from patients with heart failure with reduced ejection fraction (HFrEF; n = 12) relative to nonfailing heart tissues (n = 7). Data are shown as fold change of gene expression normalized to GAPDH. Unpaired 2-tailed t test. *P < 0.05 versus nonfailing. (D and E) RNAs isolated from H9c2 cells transfected with 100 nM MirVana miR-150 inhibitor or 15-mer control were analyzed by miR-150–specific qPCR to access the levels of miR-150 (D). Levels of Sprr1a are indicated in E. Data were normalized to U6 snRNA (D) or Gapdh (E) and expressed relative to antimiR control. Results are from 6 independent experiments with different biological samples. Unpaired 2-tailed t test. *P < 0.05 or ***P < 0.001 versus antimiR control. (F) SPRR1A protein levels were measured in whole heart lysates from miR-150 cKO mice compared with miR-150fl/fl. Results are from 6 independent experiments with different biological samples. Unpaired 2-tailed t test. **P < 0.01 versus miR-150fl/fl. Data are presented as mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts